Incorporation of Genetic Expression of Airway Epithelium With CT Screening for Lung Cancer
Lung cancer, largely the result of cigarette smoking, is the leading cause of cancer death in the United States, killing over 160,000 people in 2010, more than breast, colorectal, and prostate cancer combined. Since only 10% of heavy smokers develop lung cancer and 20% of lung cancers develop in nonsmokers, it is thought that genetic predisposition plays an important role. This study proposes to examine the genetic correlation between nasal and bronchial epithelium and to identify a patient's risk for lung cancer earlier.
Checked against the public recordLast updated Jul 24, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Weill Medical College of Cornell University
- Interventions being studied
- Genetic: Group 1; Genetic: Group 2; Genetic: Group 3
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: HEALTHY VOLUNTEER RESEARCH SUBJECTS * All study subjects should be able to provide informed consent * Males or females ages 18 years and older * Must provide HIV informed consent VOLUNTEER RESEARCH SUBJECTS WITH LUNG DISEASE * Must provide informed consent * Males and females age 18 years and older * Lung disease proven by at least one of the following: symptoms consistent with pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; and/or (6) diseases of organs with known association with lung disease * Must provide HIV informed consent Exclusion Criteria: HEALTHY VOLUNTEER RESEARCH SUBJECTS * Individuals not deemed in good overall health by the investigator will not be accepted into the study. * Habitual use of drugs and/or alcohol within the past six months (Acceptable: - Marijuana one time in three months; average of two alcoholic beverages per day; drug and/or alcohol abuse is defined as per the DSM-IV Substance Abuse Criteria). * Individuals with history of chronic lung disease, including asthma or with recurrent or recent (within three months) acute pulmonary disease will not be accepted into the study. * Individuals with allergies to atropine or any local anesthetic will not be accepted into the study. * Individuals with allergies to pilocarpine, isoproterenol, terbutaline, atropine or aminophylline will not be accepted into the study. * Females who are pregnant or nursing will not be accepted into the study VOLUNTEER RESEARCH SUBJECTS WITH LUNG DISEASE * Any history of allergies to xylocaine, lidocaine, versed, valium, atropine, pilocarpine, isoproterenol, terbutaline, aminophylline, or any local anesthetic will not be included in the study. * Habitual use of drugs and/or alcohol within the past six months (Acceptable: Marijuana one time in three months; average of two alcoholic beverages per day; drug and/or alcohol abuse is defined as per the DSM-IV Substance Abuse Criteria) * Females who are pregnant or nursing
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Weill Cornell Medical College and Weill Cornell Medical Center, Department of Genetic MedicineNew York, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 24, 2020. Always confirm current availability with the study team.